ERYTECH Makes Its 2016 Reference Document Available
The Reference Document is available on the Company’s website (http://erytech.com/fr/reference-documents.html)
and on the AMF website (http://www.amf-france.org).
The document is also available free of charge, by sending a postal
request to the registered offices of
The following documents are included in the 2016 Reference Document:
- the annual financial report;
- the management report;
- Information about fees paid to statutory auditors;
- the report of the Chairman of the Board of Directors on corporate governance and internal control;
- the auditors’ report on the report of the Chairman of the Board of Directors;
- Description of the share buy-back program;
- the Company's policies on environmental, social and corporate responsibility.
About ERYTECH: www.erytech.com
Founded in
Eryaspase consists of an enzyme, L-asparaginase, encapsulated inside
donor-derived red blood cells. L-asparaginase depletes asparagine, a
naturally occurring amino acid essential for the survival and
proliferation of cancer cells, from circulating blood plasma. ERYTECH
produces eryaspase at its own GMP-approved and operational manufacturing
site in
In addition to eryaspase, ERYTECH is developing two other product candidates that focus on using encapsulated enzymes to induce tumor starvation. The company is also exploring the use of its ERYCAPS platform for developing cancer immunotherapies and enzyme replacement therapies.
ERYTECH is listed on
Forward-looking information
This press release contains forward-looking statements, forecasts and
estimates with respect to the clinical development plans, business and
regulatory strategy, and anticipated future performance of ERYTECH and
of the market in which it operates. Certain of these statements,
forecasts and estimates can be recognized by the use of words such as,
without limitation, “believes”, “anticipates”, “expects”, “intends”,
“plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar
expressions. They include all matters that are not historical facts.
Such statements, forecasts and estimates are based on various
assumptions and assessments of known and unknown risks, uncertainties
and other factors, which were deemed reasonable when made but may or may
not prove to be correct. Actual events are difficult to predict and may
depend upon factors that are beyond ERYTECH's control. There can be no
guarantees with respect to pipeline product candidates that the
candidates will receive the necessary regulatory approvals or that they
will prove to be commercially successful. Therefore, actual results may
turn out to be materially different from the anticipated future results,
performance or achievements expressed or implied by such statements,
forecasts and estimates. Documents filed by
View source version on businesswire.com: http://www.businesswire.com/news/home/20170403005583/en/
Source: ERYTECH
ERYTECH
Gil Beyen
Chairman and CEO
or
Eric
Soyer
CFO and COO
+33 4 78 74 44 38
investors@erytech.com
or
The
Ruth Group
Investor relations
Lee Roth, +1 646 536
7012
lroth@theruthgroup.com
or
Media
relations
Kirsten Thomas, +1 508 280 6592
kthomas@theruthgroup.com
or
NewCap
Julien
Perez
Investor relations
or
Nicolas Merigeau
Media
relations
+33 1 44 71 98 52
erytech@newcap.eu